Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VB-111 and Nivolumab in Metastatic Colorectal Cancer
NCT04166383Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Aug 2020
- Primary completion
- Apr 2022
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
A Phase 2 trial of ofranergene obadenovec in colorectal cancer (CRC), sponsored by National Cancer Institute. Started Aug 2020; status: terminated.
02
Drugs
ofranergene obadenovec
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT04166383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04166383.